Skip to main content

Table 3 Artemether, lumefantrine and dihydroartemisinin: 90% CI for relevant PK parameters

From: Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem®) for bioequivalence in a randomized, open-label, two-period study

Formulation Analyte PK Geometric mean ratio
variable Estimate Lower Upper
90% CI* 90% CI*
80/480 mg vs four standard tablets Artemether AUClast 0.95 0.89 1.01
  Cmax 0.97 0.89 1.06
  AUCinf 0.95 0.89 1.02
  Lumefantrine AUClast 1.00 0.93 1.08
   Cmax 0.97 0.89 1.05
   AUCinf 1.00 0.92 1.09
  Dihydroartemisinin AUClast 0.98 0.93 1.04
   Cmax 0.96 0.88 1.05
   AUCinf 1.00 0.95 1.05
60/360 mg vs three standard tablets Artemether AUClast 1.02 0.94 1.10
  Cmax 1.06 0.95 1.18
  AUCinf 1.00 0.93 1.09
  Lumefantrine AUClast 0.89 0.83 0.96
   Cmax 0.87 0.81 0.94
   AUCinf 0.89 0.83 0.96
  Dihydroartemisinin AUClast 1.00 0.94 1.07
   Cmax 1.02 0.94 1.12
   AUCinf 1.03 0.97 1.10
  1. *CI confidence interval.
  2. Model: The log transformed PK parameter data were analyzed using a linear model with treatment, sequence, period and subject nested within sequence as fixed factors.